Filing Flows › vTv Therapeutics (VTVT) › Q4 2024
vTv Therapeutics (VTVT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
vTv Therapeutics (VTVT) reported revenue of $17K for the fourth quarter 2024 (Q4 2024).
vTv Therapeutics, Q4 2024: revenue $17K, net loss $4.4M, operating cash flow −$4.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17K | — | — |
| Operating profit | −$4.9M | — | — |
| Net earnings | −$4.4M | — | — |
| Operating cash flow | −$4.8M | — | — |
What changed
Revenue was $17K in Q4 2024.
Operating costs exceeded revenue by $4.9M, an operating margin of -28776.5%. The quarter ended with a net loss of $4.4M. Minority interests bore $803K of it: to shareholders the quarter was a loss of $3.6M.
Operating cash flow was −$4.8M. Non-cash charges added back $22K of depreciation and $825K of share-based compensation. Working capital and other items used $1.2M.
Questions
What was vTv Therapeutics' revenue in the fourth quarter 2024?
vTv Therapeutics (VTVT) reported revenue of $17K for the fourth quarter 2024 (Q4 2024).
Source: vTv Therapeutics 10-K on SEC EDGAR.